June 8, 2021: Dr. Diana Zuckerman, president of NCHR, speaks out against FDA’s approval of the ineffective Alzheimer’s drug aduhelm.
Read More »Tag: Aducanumab
NCHR Statement at FDA Alzheimer’s Advisory Committee Meeting On Aducanumab
November 6, 2020: Aducanumab could be promising, but we need better evidence before approving it.
Read More »